RHEUMOCAM 1.5MG/ML ORAL SUSPENSION FOR DOGS

Nazione: Canada

Lingua: francese

Fonte: Health Canada

Principio attivo:

Méloxicam

Commercializzato da:

CHANELLE PHARMACEUTICALS MANUFACTURING LIMITED

Dosaggio:

1.5MG

Forma farmaceutica:

Suspension

Composizione:

Méloxicam 1.5MG

Via di somministrazione:

Orale

Confezione:

15/42/100/200ML

Tipo di ricetta:

Prescription

Gruppo terapeutico:

Chiens

Dettagli prodotto:

Numéro de groupe d'ingrédients actifs (GIA) :0131676001

Stato dell'autorizzazione:

APPROUVÉ

Data dell'autorizzazione:

2012-07-26

Foglio illustrativo

VERSION 6
09/07/2023
CARTON FOR 15 ML, 42 ML, 100 ML OR 200 ML BOTTLE
ENGLISH FRONT PANEL
DIN:
02389932
Rheumocam 1.5 mg/ml Oral Suspension for Dogs
Meloxicam Oral Suspension, Mfr. Std.
Veterinary Use Only
KEEP OUT OF REACH OF CHILDREN.
SHAKE WELL BEFORE USING
Pack size:
15 ml, 42 ml, 100 ml, 200 ml
ENGLIGH SIDE PANEL
INDICATIONS:
Non-steroidal anti-inflammatory drug (NSAID) indicated for the
alleviation of
inflammation and pain in both acute and chronic musculo-skeletal
disorders in dogs.
DOSAGE:
Administer orally mixed with food. On the first day of treatment a
single dose of
0.2 mg meloxicam/kg bodyweight should be given. Treatment is to be
continued by once
daily oral administration (i.e. at 24 hour intervals) at a maintenance
dosage of 0.1 mg
meloxicam/kg body weight.
For additional information on the dosage and instructions for use,
please refer to the enclosed
insert.
CONTRAINDICATIONS:
Rheumocam 1.5 mg/ml oral suspension for dogs should not be
administered if gastric or intestinal ulceration or bleeding is
suspected; if there is evidence of
cardiac, hepatic or renal disease; or if there is evidence of a
haemorrhagic disorder or
individual hypersensitivity to the product. Do not administer
concurrently, other steroidal or
nonsteroidal anti-inflammatory drugs (NSAIDs), aminoglycoside
antibiotics or anti-coagulant
agents. Pre-treatment with other steroidal or nonsteroidal
anti-inflammatory drugs (NSAIDs)
may result in additional or increased effects. Depending on the
pharmacokinetic properties of
the products used previously, an appropriate treatment-free period
with such drugs should be
observed before commencement of treatment.
Do not use if there is evidence of dehydration, hypovolemia or
hypotension, because of the
increased risk of renal injury caused by the destruction of protective
prostaglandins secreted
by the kidneys in this risk situation.
CAUTIONS:
Not approved for use in cats. Rheumocam 1.5 mg/ml oral suspension for
dogs
should not be administered to breeding, pregnant or lactating dogs. Do
not